Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
HER2 promotes the growth of cancer cells and makes them particularly aggressive.
|
31134823 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The role of anti-HER2 therapy is unclear in women with other gynecologic malignancies but is being evaluated.
|
31833974 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The human epidermal growth factor receptor 2 (HER2) plays an essential role in the tumorigenesis and tumor progression in cancer.
|
31829777 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial.
|
31620931 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MCM2-LI was not shown to be predictive of disease recurrence during the median follow-up of 5.3 years but was shown to be useful to distinguish aggressive-type HER2-amplified breast carcinomas with high malignancy grade and hormone receptor negativity.
|
30358612 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Human epidermal growth factor receptor 2 (HER2) is an attractive target for cancer therapy, although a large fraction of tumors that express HER2 may still resist first-line therapies.
|
31836485 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The phase II/III GATSBY study (NCT01641939) showed that trastuzumab emtansine did not have an efficacy benefit over taxane in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic gastric or gastroesophageal junction cancer.
|
31721447 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Data on immune checkpoint inhibitor efficacy in patients with human epidermal growth factor receptor 2-positive (HER2+) advanced gastric/gastroesophageal junction (G/GEJ) cancer are lacking.
|
31087200 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Abnormalities in the expression levels of EGFR/HER2 are found in many different types of human cancer; therefore, the design of dual inhibitors of EGFR/HER2 is a recognized anti-cancer strategy.
|
31828486 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Taken together, ERBB2 is required for the dysregulation of cancer-related genes, such as <i>MED24</i>, during lung tumor development.
|
31248101 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Graphical abstract Schematic presentation of amplified imaging of human epidermal growth factor receptor 2 (HER2) dimerization on cancer cell surfaces by using a co-localization triggered DNA nanoassembly (CtDNA).
|
31197538 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In summary, our group A cases account for 1.5% of breast cancers, and 10.7% of all HER2/neu-amplified cancers classified as such based on 2013 ASCO/CAP criteria.
|
30121371 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In summary, these findings demonstrated that circ-ERBB2 functions as an oncogene in GC and might be useful in developing promising therapies for this fatal malignancy.
|
30853181 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The American Joint Committee on Cancer eighth edition manual (AJCC8) departed from traditional anatomic staging by incorporating biological factors such as grade, hormone and HER2 receptor status into a novel prognostic staging model.
|
30926158 |
2019 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
New studies suggested that HER2 expression is correlated with cancer stem cell (CSC) markers in breast cancer.
|
31211468 |
2019 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Prevalence and role of HER2 mutations in cancer.
|
30951733 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We report screening data from the iMYC trial, an ongoing phase II study assessing ibrutinib monotherapy in advanced pretreated MYC- and/or HER2-amplified oesophagogastric cancer, representing the first attempt to prospectively identify MYC amplifications in this tumour type for the purposes of therapeutic targeting.
|
31606655 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To account for cancer cell heterogeneity, a first, dynamic model was expanded to a second model including two distinct cell phenotypes, with implications for different conformational states of HER2, i.e. monomeric or homodimeric.
|
31481718 |
2019 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
SORLA protein levels in cancer cell lines and bladder cancers correlates with HER2 levels.
|
31138794 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
After adjustment for the effect of dose group, patients with Her 2 negative cancer can expect shorter LPFS than those with Her 2 positive cancer (HR = 2.6, 95% CI = 1.5-4.4, <i>p</i> < 0.0005).
|
31192116 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, our data indicate that SLFN and MTFN can reduce cancer cell viability via both collaborative and differential effects and suggest that MTFN increases SLFN effectiveness by targeting common molecules/pathways downstream of HER2 and key for CSC signaling.
|
31474154 |
2019 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here we used the DEPArray system to identify and isolate CTCs from metastatic triple negative breast cancer (TNBC) patients and performed single-cell NanoString analysis to quantify cancer pathway gene expression in HER2-positive and HER2-negative CTC populations.
|
31238530 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
No study has investigated the biological function of BCLIN25, serving as a novel HER2 subtype-specific lincRNA, in human disease, especially in malignancy.
|
31801944 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The patients in the SNB group had a higher rate of estrogen receptor-positive and triple-negative breast cancers, but a lower rate of human epidermal growth factor receptor 2 (HER2)-positive cancer (p < 0.001).
|
31342364 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Invasive lobular, low-grade, or HER-2-negative cancer is more detectable with DBT than with conventional FFDM in patients with dense breasts, but cancers surrounded by mostly glandular tissue might be missed with both techniques.
|
30627022 |
2019 |